Viscoelastic Hemostatic Assays and Platelet Function Testing in Patients with Atherosclerotic Vascular Diseases

Matej Samoš 1,*†, Ingrid Škorňová 2,†, Tomáš Bolek 1, Lucia Stančiaková 2, Barbora Korpálová 1, Peter Galajda 1, Ján Staško 2, Peter Kubisz 2 and Marián Mokáň 1

1 Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia; ato.bolek@gmail.com (T.B.); barbora.korpallova@gmail.com (B.K.); peter.galajda@uniba.sk (P.G.); mokanmarian@gmail.com (M.M.)
2 National Centre of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 036 59 Martin, Slovakia; inkaskornova@gmail.com (I.Š.); lstanciakova@gmail.com (L.S.); jan.stasko@uniba.sk (J.S.); peter.kubisz@uniba.sk (P.K.)
* Correspondence: matej.samos@gmail.com
† These authors share first authorship, their contribution on study design and manuscript preparation was equal.

Abstract: Platelets play crucial role in acute vascular atherosclerotic diseases, including myocardial infarction and stroke. Additionally, platelet aggregation is a key target of antiplatelet agents, forming the keystone of pharmacotherapy of various atherosclerotic cardiovascular diseases. Thromboelastography and thromboelastometry, representing currently available viscoelastic hemostatic assays (VHA), are designed as whole blood, real-time analyzers of clot formation and clot resolution. These assays could, in theory, overcome some limitations of currently available platelet function testing assays. This article reviews the current experience with the use of VHA for platelet function testing and for monitoring of the response to antiplatelet therapy.

Keywords: viscoelastic hemostatic assays; thromboelastometry; thromboelastography; platelet function testing; atherosclerotic vascular disease

1. Introduction

Activation and aggregation of platelets plays an important role in acute vascular atherosclerotic diseases, including myocardial infarction and stroke. Additionally, platelet aggregation is a key target of antiplatelet agents, such as acetylsalicylic acid (ASA, aspirin), P2Y12 adenosinediphosphate (ADP) receptor blockers (ADPRB) and glycoprotein IIb/IIIa blockers. Thus, these agents are often used to treat or to prevent atherosclerotic vascular disease; nevertheless, the insufficient response to these agents (high on-treatment platelet reactivity (HPR), or antiplatelet therapy resistance) has been repeatedly connected with higher risk of vascular events, and increased mortality. This raises the question about the need for platelet function testing to identify individuals with HPR or impaired responses to antiplatelet drugs. Although several methods, such as light transmission or impedance aggregometry, vasodilator-stimulated phosphoprotein (VASP) phosphorylation assessment, the Platelet Function Analyzer (PFA)-100® assay or Verify Now® assay have been introduced for platelet function/antiplatelet therapy response testing [1–3], these methods have their disadvantages.

Viscoelastic hemostatic assays (VHA), available as thromboelastography and thromboelastometry, are designed as whole-blood, real-time analyzers of clot formation and lysis [4,5]. These assays are, in theory, capable of overcoming some limitations of currently available platelet function tests, such as longer turnaround times, the need for special equipment and skilled staff, and an inability to test the platelet function in point-of-care settings. This article reviews current experience with the use of VHA for platelet function
testing (PFT) and for monitoring of the response to antiplatelet drugs in patients with atherosclerotic vascular diseases.

2. Viscoelastic Hemostatic Assays and Platelet Function Testing

2.1. Platelet Dysfunction and Adverse Vascular Events

As already mentioned, platelet dysfunction (abnormal platelet activation and aggregation) plays an important role in cardiac adverse events [6]. HPR predicts future ischemia in patients undergoing percutaneous coronary interventions (PCI) for acute coronary syndromes (ACS) [7–9], as well as in those after coronary stenting for stable coronary artery disease (SCAD) [10–12]. Moreover, HPR seems to be related to vascular dysfunction in patients with SCAD on antiplatelet agents [13], and platelet activation after PCI could independently predict worse clinical outcome and may be helpful in risk stratification [14]. In another study, high mean platelet volume—a simple indicator of platelet size that correlates with platelet activation and aggregability—was associated with a significantly increased incidence of long-term adverse events [15]. In addition, platelet dysfunction and abnormal (high) platelet activation or abnormal platelet aggregation is independently associated with the risk of ischemic stroke [16–18], lower limb ischemia [19], diabetic vascular disease [18,20] and vasculogenic erectile dysfunction [21]. Summarizing, platelet dysfunction with abnormal platelet activation and aggregation is connected with various cardiovascular ischemic diseases. Therefore, unsurprisingly, antiplatelet therapy forms currently the keystone of pharmacology of these diseases.

Going further, inadequate therapeutic response—or so called HPR on P2Y12 ADPRB [8–12,14,22–25], and aspirin [25–27] (with a lower level of evidence)—is associated with unfavorable clinical course, and predicts independently future thrombotic adverse events in those undergoing coronary stent implantation (both for ACS and SCAD). For example, in a sub-analysis of the randomized GRAVITAS (Gauging Responsiveness with a Verify Now P2Y12 assay: Impact on Thrombosis and Safety) study [24], HPR (defined as >208 P2Y12 reaction units when examined with a point-of-care Verify Now® assay at 12 to 24 h after PCI) was connected with a higher risk of adverse ischemia at 60 days and at 6 months (at 60 days: hazard ratio [HR]: 0.18; 95% confidence interval [CI]: 0.04–0.79; \( p = 0.02 \); at 6 months: HR: 0.43; 95% CI: 0.23–0.82; \( p = 0.01 \)). Additionally, HPR remains independently associated with adverse vascular events (including stent thrombosis) also in individuals treated with novel P2Y12 ADP receptor blockers with stronger platelet inhibition, such as prasugrel and ticagrelor [28–30]. Summarizing the data, HPR despite oral antiplatelet agents has been consistently connected with the risk of adverse ischemia; thus identifying individuals with insufficient antiplatelet therapy response might help in preventing these possibly fatal events. Several platelet function tests have been introduced for this purpose.

2.2. Platelet Function Testing in Cardiovascular Medicine

As already discussed, PFT might be used to search for patients with HPR and to predict platelet response to ASA and P2Y12 ADPRB therapy. In addition, several previously published papers pointed to the fact that this testing might be useful for the identification and management of platelet-related bleeding during cardiac [31–35] and non-cardiac surgery [36,37], or to identify patients with inherited platelet disorders [38,39]. Several platelet function tests have been established for PFT in cardiovascular diseases. These include light transmission and multiple electrode aggregometry [40], the Verify Now® assay [41,42], VASP phosphorylation (VASP-P) flow cytometric assessment [43], and PFA-100® analysis [40].

Light-transmission (optical) aggregometry (LTA), a turbidometry-based assay, still represents a “gold standard” in PFT [40]. The assay assesses platelet aggregation in platelet-rich plasma (PRP), the aggregation is induced by non-specific (collagen, epinephrine) or drug-specific (arachidonic acid, ADP) inducers (platelet agonists). The assay detects differences (with a photometer) in light transmission after a selected inducer is added to
Measurement of aggregation is displayed as an aggregation curve which presents the intensity of changes in the light transmission of examined PRP. The maximal extent of platelet aggregation is then expressed in percentages (0% represents no aggregation, 100% represents maximal possible platelet aggregation). Samples can be tested with a large scale (and at different concentrations) of inducers, which allows different pathways of platelet activation to be tested, or treatment response to different antiplatelet agents to be tested. The major disadvantages of the assay include a need for special laboratory equipment and specially skilled laboratory staff to perform the analysis, the fact that the analysis itself is time-consuming, the pre-analytical demands of the assay (PRP needs to be prepared and analyzed within one hour of blood sampling), and the non-specificity of the method.

Multiple electrode (impedance) aggregometry [40] assesses changes in electrical impedance between multiple electrodes after inducing the aggregation by a platelet inducer. The method is similar to LTA except that it uses a whole blood sample, and thus there is no need to prepare PRP. The assay can be used in point-of-care (POC) settings, and contains five channels for simultaneous analysis of different samples or simultaneous analysis of one sample with different inducers. The assay is more cost-demanding compared to LTA, and the platelet response to the inducer is non-specific.

The Verify Now® (Accumetrics, San Diego, CA, USA) system is a POC assay [42] based on a modified aggregometry with a use of drug-specific inducers (arachidonic acid, ADP) and thrombin receptor-activating peptide (TRAP). The assay assesses the agglutination of fibrinogen-coated beads by platelets stimulated by the inducer in whole blood sample with citrate. The Verify Now® P2Y12 assay detects the extent of the P2Y12 blockade by a P2Y12 ADPRB. The system has two assay channels. P2Y12 ADPRB inhibits aggregation in the ADP-containing channel but not in the second channel with TRAP. Aggregation in both channels is assessed as the change (increase) in light transmission and is reported in PRU (platelet response units). Likewise, the Verify Now® Aspirin assay [41] contains fibrinogen-coated beads and arachidonic acid (specific inducer), platelet activation is induced with specific inducer, and activated platelets then bind to the fibrinogen-coated beads causing agglutination. The degree of light transmission is proportional to aggregation; ASA inhibits this agglutination. The assay is quick, and user friendly; nevertheless, it is less sensitive to the platelet ADP signaling pathway compared with VASP-P analysis [44].

VASP-P assessment [43] accurately and specifically detects platelet response on P2Y12 ADP receptor blockers. The test is performed ex vivo on a flow cytometer. A sample of citrated blood is incubated with prostaglandin E1 and with prostaglandin E1 plus ADP. After cellular permeabilization, VASP-P is labeled by immunofluorescence using a specific monoclonal antibody. Dual color flow cytometry then allows final calculation of the “platelet reactivity index” (PRI) using corrected VASP fluorescence intensities in the presence of prostaglandin E1 alone (resting) or prostaglandin E1 plus ADP (activated platelets). The major advantage of the assay is its specificity for the ADP signaling pathway. However, examination requires a laboratory equipped with a flow cytometer and skilled laboratory staff, and is cost-demanding. These disadvantages limit its use in daily clinical practice.

PFA-100® (Siemens, Munich, Germany) assesses the cessation of high-shear blood flow by the platelet plug [40]. A quick and simple POC assay needs a low volume of sample and no sample preparation. In this method, whole blood with citrate flows through a capillary at a high shear rate within the test cartridge that ends in a membrane filled with a platelet agonist (inducer). The time until clot build-up occludes the aperture (closure time) correlates with platelet aggregation rate. The examination itself can be performed with cartridges containing different inducers—collagen, ADP, prostaglandin E1, epinephrine—which can be used, similar to LTA, to test different pathways of platelet activation. The disadvantages of the method are that it is dependent on hematocrit and von Willebrand factor levels, the non-specificity of platelet activation during the test, and that it requires pipetting.
Considering the aforementioned disadvantages of already available platelet function tests, the key question of this article is whether VHA assay-based platelet function testing might provide additional benefits in clinical management of platelet dysfunction or antiplatelet drugs in patients with atherosclerotic vascular diseases (compared to already available platelet function testing).

2.3. Thromboelastography and Thromboelastometry: Assays Principle, Advantages and Disadvantages

Both thromboelastography (TEG®, Haemoscope, Haemonetics, Niles, IL, USA) and rotational thromboelastometry (ROTEM®, Instrumentation Laboratory, Bedford, MA, USA) are designed as POC VHA that use a whole blood sample, which is examined in real time, with slight differences in operating mechanisms. TEG® (Table 1) and ROTEM® (Table 2) assess clot formation, clot lysis and clot strength by assessing and displaying the amount of a continuously applied rotational force that is transmitted to an electromechanical transduction system by the forming clot (Figure 1). In the thromboelastography, a rotating cylindrical cup (with a 340 µL whole blood sample) oscillates through 4°45′ every 5 s while a pin on a torsion wire is fixed in the blood sample. As the strength of the forming clot increases, more rotation is transmitted to the wire and is recognized by a transducer. In the thromboelastometry system, a cylindrical cup (with a 340 µL of whole blood sample) stands fixed while a pin swinging on a ball-bearing mechanism oscillates through 4°75′ every 6 s applying a constant force. As the viscoelastic clot strength increases, the (pin) rotation is blocked and is displayed with a sensor (a charge-coupled device image sensor system) [4,45,46].

Table 1. Thromboelastography (TEG®).

| Assay Principle | Viscoelastic hemostatic assay, uses 340 µL of whole blood in a rotating cylindrical cup while a fixed pin on a torsion wire is suspended in the blood, coagulation is activated by selected activators in a pre-defined assay |
| Manufacturer | Haemoscope, Haemonetics, Niles, IL, USA. |
| Platelet Function Testing | Yes (Platelet mapping assay specifically designed for thromboelastography is commercially available) |

| Parameter (Calculation) | Information Provided |
|-------------------------|----------------------|
| R (Reaction rate) | the time elapsed from the coagulation trigger until the formation of a clot of 2 mm |
| K (Kinetics time) | the time elapsed from 2 to 20 mm |
| MA (Maximum amplitude) | the maximum amplitude of the signal |
| LY30 (Lysis 30) | percentage of remaining clot stability in relation to the MA value at 30 min after R |

| Assay | Description |
|-------|-------------|
| Kaolin | Kaolin acts as contact activators. |
| Rapid TEG | Reagent contains tissue factor and kaolin as inducers. |
### Table 1. Cont.

| Assay           | Description                                                                                                                                 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| HTEG            | Reagent with lipophilized heparinase to neutralize unfractionated heparin. Used in conjunction with kaolin to measure heparin effect.          |
| Functional fibrinogen | Reagent with tissue factor and abciximab (glycoprotein IIb/IIIa platelet receptor blocker), inhibiting platelet contribution to clot formation. Allows qualitative measurement of the fibrinogen contribution to clot strength independent of platelets. |
| Native          | Native whole blood sample analyzed following only recalcification. Impractical for clinical use given long R time.                             |
| Platelet mapping | Assay uses heparinized blood mixed with ActivatorF (reptilase and activated factor XIII). Sufficient heparin is present to entirely suppress the generation of thrombin while fibrinogen is converted to fibrin and cross-linked due to the presence of reptilase and activated factor XIII. Subsequent addition of either arachadonic acid (AA) or adenosine diphosphate (ADP) allows measurement of the platelet activation response to these inducers in the absence of thrombin. These results are compared to kaolin analysis to determine platelet response to AA and ADP. |

### Table 2. Rotational thromboelastometry (ROTEM®).

| Assay Principle | Viscoelastic hemostatic assay, uses 340 µL of whole blood in a fixed cylindrical cup while a pin suspended on a ball-bearing mechanism oscillates with the application of a constant force, coagulation is activated by selected activators in a pre-defined assays |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Manufacturer    | Instrumentation Laboratory, Bedford, MA, USA                                                                                               |
| Platelet Function Testing | No (FIBTEM indirectly assesses platelet function, platelet mapping assay could be adapted for ROTEM®)                                       |

| Parameter      | Calculation                                                                 | Information Provided                           |
|----------------|-----------------------------------------------------------------------------|-----------------------------------------------|
| CT (Clotting time) | the time elapsed from the coagulation trigger until the formation of a clot of 2 mm | Time from initiation of clotting process until clot starts to form |
| CFT (Clot forming time) | the time elapsed from 2 to 20 mm                                              | Flags the speed of formation of a solid clot |
Table 2. Cont.

| Parameter                        | Calculation                                           | Information Provided                                                                 |
|----------------------------------|-------------------------------------------------------|---------------------------------------------------------------------------------------|
| **MCF** (Maximum clot firmness)  | the maximum amplitude of the signal                   | Reflects the maximum clot strength                                                    |
| **LI 30** (Lysis index after 30 min) | percentage of remaining clot stability in relation to the MCF value at 30 min after CT | Reflects loss of clot stability                                                       |

| **Assay** | **Activator/Inhibitor** | **Information Provided**                                                                 |
|-----------|-------------------------|---------------------------------------------------------------------------------------|
| INTEM     | Contact activation      | Fast assessment of clot forming, fibrin polymerization, and fibrinolysis through the intrinsic pathway |
| HEPTEM    | Contact activation + heparinase | ROTEM measurement without heparin contribution: specific detection of heparin (compared to INTEM), measurement of clotting in heparinized ones |
| EXTEM     | Tissue factor activation | Fast assessment of clot forming, fibrin polymerization, and fibrinolysis through the extrinsic pathway |
| FIBTEM    | Tissue factor activation + platelet inhibition | ROTEM measurement without platelets: qualitative measurement of fibrinogen status |
| APTEM     | Tissue factor activation + aprotinin | In vitro fibrinolysis inhibition: fast detection of lysis when compared with EXTEM |
| NATEM     | Recalcification only = classical TEM (thromboelastometry) | Sensitive measurement of the equilibrium of coagulation activation or inhibition |

Figure 1. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM).

Both assays [47] graphically record kinetic changes of citrated whole blood samples during clot forming and its dissolution in the form of thromboelastogram, mapping various phases of hemostasis. The technology leans on a constantly oscillating cup/pin in a blood sample with reagents. There is no rotation blockage, if there is no clot formation. In a forming clot, there is a rotation blockage due to a link between the cup wall and pin. Thus, free rotation corresponds to an amplitude of 0 mm and no rotation corresponds to an amplitude of 100 mm. The interpreting software determines clot formation parameters in
real time during the test, and these parameters are subsequently graphically interpreted in the thromboelastogram (Figure 1).

A thromboelastography device can analyze two samples at the same time; a thromboelastometry device can analyze four samples at the same time. While both thromboelastography and thromboelastometry provide, in general, the same data on the formation and strength of thrombi, these data are not interchangeable. This is due to different assays and coagulation inducers, as well as due to different nomenclature [46]. The most important advantages of these VHA are rapidity, complexity, and the ability to test a whole blood sample in a point-of-care setting.

Both assays have their limitations [4]. In fact, hemostasis is associated with a wide range of normal values, as there is a high variability in the components of hemostasis (platelet count, platelet activity, fibrinogen levels, glycoprotein IIb/IIIa receptor number, etc.). Therefore, in optimal settings, each patient should have baseline VHA values before the therapy or procedure to create an internal, personalized reference value for comparison. Additionally, there are difficulties with assay standardization and validation (as the method continues to diversify in activators, modifications and equipment). Thromboelastography, as well as thromboelastometry may be performed with a large scale of inducers and inhibitors which might alter the specificity of the assay. These issues have been, in part, overcome by the use of computer software analysis allowing better standardization. Further achievement in standardization has been made by the use of individual temperature control, by the use of disposable cups and pins, and the use of standard activators of coagulation (such as kaolin).

2.4. Platelet Function Testing with Thromboelastography

The TEG® Platelet Mapping™ Assay (Haemoscope Corporation, Niles, IL, US) is a thromboelastography assay designed for PFT which relies on evaluation of clot strength to allow a quantitative measurement of platelet function. Using this assay, the maximal haemostatic activity is assessed in a kaolin activated whole blood sample with citrate. Assay performs measurements with heparin to eliminate thrombin activity [48], the contribution of the ADP or thromboxane A2 platelet receptors to the clotting is tested by the addition of arachidonic acid or ADP. The assay was evaluated in several previously published studies. First, Tantry et al. [48] evaluated the sensitivity of the assay for detection of ASA resistance (compared to arachidonic acid-induced platelet aggregation measured with LTA). In this study, enrolling 223 patients in long-term ASA therapy and six healthy individuals who received 325 mg of aspirin, the platelet aggregation assessed by LTA strongly correlated with aggregation assessed in the whole blood by the TEG® Platelet Mapping™ assay ($r = 0.85, p < 0.001$). All of the patients with non-compliance (7 patients) had high platelet aggregation by both methods (TEG and LTA). Subsequently, Alström et al. [49] tested the effect of a clopidogrel bolus dose on platelet inhibition in 28 patients on aspirin therapy undergoing coronary angiography/PCI with the use of TEG® Platelet Mapping™ assay and found significantly ($p = 0.002$) decreased platelet reactivity (platelet inhibition) with platelet mapping. Bochsen et al. [50,51] examined maximal platelet reactivity (MPR) and platelet reactivity response to ADP stimulation using thromboelastography with platelet mapping in healthy blood donors (43 individuals) and patients planned for coronary artery bypass graft (CABG) surgery (22 patients) and demonstrated that MPR and platelet response to ADP was higher in the CABG patients than in the healthy controls, speculating that this observation may reflect the higher risk for ischemia in the cohort of CABG patients. In another prospective observational study [52] the authors assessed platelet reactivity with TEG® Platelet Mapping™ in patients presenting for orthopedic trauma surgery or acute general surgery who received clopidogrel (21 patients), aspirin (18 patients) or no antiplatelet therapy (20 patients) prior admission. In this study, TEG® Platelet Mapping™ identified statistically significant inhibition of platelets due to antiplatelet therapy. Nevertheless, the authors reported an overlap in platelet receptor inhibition between the three examined groups of patients, which could, in their opinion, limit the
clinical utility of the assay. Subsequently, several other studies reported that the use of TEG® Platelet Mapping™ could predict postoperative blood loss among patients who underwent cardiac [53–59], trauma or other non-cardiac surgery [60–64] and received antiplatelet therapy.

Furthermore, several other studies or cases addressed the issue of monitoring the response on aspirin [65–67], clopidogrel [68–72] and ticagrelor [72–74] with TEG® Platelet Mapping™ assay. Looking at the most recent studies, Cheng et al. [71] reported a usefulness of several TEG® Platelet Mapping™ parameters (including Net platelet clot strength as the strongest predictor) for determining clopidogrel HPR in post-PCI patients. Yang et al. [72] tested the effect of clopidogrel and ticagrelor on platelet activity in patients with transient ischemic attack or minor stroke. Platelet on-treatment response was assessed with TEG® Platelet Mapping™. The primary outcome of this study was the number of patients with HPR (maximum amplitude induced by adenosine diphosphate > 47 mm). The study enrolled 339 patients, 170 were randomized to ticagrelor plus ASA and 169 to clopidogrel plus ASA. The authors reported that, compared with clopidogrel, the rate of HPR in ticagrelor-treated patients was significantly lower (12.2% versus 30.0%, p < 0.001). Additionally, in this study, ticagrelor was superior in platelet inhibition measured by the TEG® Platelet Mapping™ assay. Finally, Zhang et al. [75] reported in their analysis of 467 consecutive patients with myocardial infarction undergoing PCI that by receiver operating characteristic curve analysis, the TEG® Platelet Mapping™ assay rate of ADP inhibition had the best predictive value of future hemorrhagic events. This suggests possible role of the assay in predicting bleeding (not only to predict ischemia) in patients after recent PCI.

Summarizing this issue, currently available data suggest possible clinical utility of the TEG® Platelet Mapping™ assay in the settings of predicting peri-operative blood loss in patients who take antiplatelet medication and need cardiac or non-cardiac surgery, and in the prediction of treatment response (identification of antiplatelet therapy resistance) on most commonly used antiplatelet agents (aspirin, clopidogrel and ticagrelor).

2.5. Platelet Function Testing with Thromboelastometry

Thromboelastometry is another VHA available in routine clinical practice. This method, as mentioned, differs in the method of clot strength detection (a rotating pin in a fixed cup in thromboelastometry opposed to a fixed pin and a rotating cup in thromboelastography), reagents (with different coagulation inducers) and slightly in measured parameters. In fact, there are limited experiences in platelet function testing with thromboelastometry (compared to thromboelastography). First, the assay has been tested for the evaluation of treatment response on antiplatelet therapy. In one of the first analyses of the use of thromboelastometry for measuring the response to dual antiplatelet therapy (aspirin plus clopidogrel), we performed a pilot prospective study [76] in which samples from acute ST elevation myocardial infarction (STEMI) patients (on dual antiplatelet therapy) were analyzed with thromboelastometry (using EXTEM® and FIBTEM® reagents) and compared with samples from healthy blood donors (with no antithrombotic therapy). In this study, clotting time was significantly prolonged and maximum clot firmness was significantly higher in patients compared to controls. Nevertheless, when a sub-analysis of patients with acute MI was performed, using ROTEM® analysis, we were not able to discriminate HPR and normal response to antiplatelet therapy. This observation suggested that for antiplatelet therapy response testing a more specific “platelet mapping assay” for thromboelastometry would be needed. At the time of the study, there was no such assay validated. Nevertheless, Schäfert et al. [77] reported their first experiences with modified rotational thromboelastometry with platelet mapping assay prior to our study. In this study, platelet aggregability was determined from blood samples taken from 22 adult healthy individuals and patients without or with antiplatelet drugs (clopidogrel with or without aspirin) using three different assays: multiple electrode aggregometry, thromboelastography with platelet mapping assay using both inducers—ADP and arachidonic acid, and its adapted version in rotational thromboelastometry. The authors of this study reported
that the specificity for detection of ADP receptor blocker-induced platelet inhibition was
low in both assays; however, the differences in frequency distribution between the results
obtained in thromboelastography and thromboelastometry were not statistically significant.
Subsequently, Braun at al. [78] studied the antiplatelet and anticoagulant action of clopi-
dogrel plus heparin (26 patients) versus prasugrel plus bivalirudin (25 patients) versus
untreated controls (20 individuals) with multiple electrode aggregometry and rotational
thromboelastometry in patients with STEMI. In this study, in rotational thromboelastome-
try analysis, there were no differences in reducing clot formation time between studied
antiplatelet/anticoagulation agent regimens and both regimens did not affect maximum
clot firmness compared to the control group. This observation confirmed our observa-
tion of low sensitivity of standard assays of rotational thromboelastometry in detecting
P2Y12 receptor blocker-induced changes in platelet reactivity. Unfortunately, to date, there
has been no other larger study evaluating the ability of rotational thromboelastometry
with a platelet mapping assay (which was originally developed for thromboelastography)
to assess the response on antiplatelet agents in patients undergoing invasive vascular
procedures. Furthermore, clinical experiences with platelet function test specifically de-
signed for thromboelastometry are very limited [79], with one prospective study [80]. This
novel method is designed as a combination of standard thromboelastometry and whole
blood impedance aggregometry assessed on the ROTEM platelet module (Instrumentation
Laboratory, Werfen, Munich, Germany), with the use of platelet-specific reagents (contain-
ing specific platelet inducer) [79,80]. ADPTEM reagent contains ADP, ARATEM reagent
contains arachidonic acid, and TRAPTEM reagent contains thrombin receptor-activating
peptide. First experience with the assay was reported by Nissen et al. [80] who studied the
assay on blood samples (with citrate or hirudin) collected from 121 healthy individuals
and tried to establish reference intervals for platelet aggregation for each of the reagents
(ADPTEM, ARATEM and TRAPTEM). The authors reported that in citrate tubes, the stabili-
ty of the ROTEM platelet assays was 60–120 min, while the stability in hirudin tubes was
30–60 min and established combined and gender-specific reference intervals for all three
assays. Nevertheless, there are no other reports of clinical experiences with this assay and,
therefore, the assay still needs appropriate validation.

Similarly, with thromboelastography, several studies tried to evaluate the use of rota-
tional thromboelastometry for procedural bleeding risk assessment and blood replacement
therapy in patients undergoing cardiac surgeries. Looking more closely at these trials,
Ogawa et al. [81] observed a significant correlation between thromboelastometry test
FIBTEM-amplitude at 10 min and fibrinogen levels (r = 0.87; p < 0.001) and between test
EXTEM and INTEM-A10 (amplitude at 10 min after the initiation of clot formation) values
and platelet count (r = 0.72 and 0.67; p < 0.001) in patients undergoing procedures with
cardiopulmonary bypass. The authors suggested the ability of rotational thromboelastome-
try testing with FIBTEM assay to quickly detect decreasing levels of fibrinogen in patients
who underwent cardiopulmonary bypass. In another study enrolling patients undergoing
CABG surgery on antiplatelet agents (aspirin alone or aspirin plus clopidogrel), Tarzia
et al. [82] reported an observation of comparable pre-operative classic coagulation tests
and traditional ROTEM parameters in those with major bleeding and those without a bleeding
event. Nevertheless, the authors reported that the area-under-the-curve in the EXTEM
test was significantly lower in patients with major hemorrhage than non-bleeders. Fi-
ally, Azarfarin et al. [83] studied the relation between maximum clot firmness in rotational
thromboelastometry and bleeding after CABG surgery in patients on clopidogrel and found
that the need for chest tube drainage and for blood product transfusion were significantly
higher in those with maximum clot firmness below 50 mm. Furthermore, in patients who
experienced postoperative bleeding of 1 L of blood or more, several rotational thromboe-
lastometry parameters including maximum clot firmness (tested with INTEM, EXTEM and
HEPTEM reagents) were significantly lower than in those with postoperative bleeding < 1
L. This observation suggested that rotational thromboelastometry might be useful for the
prediction of increased risk of hemorrhage after CABG in patients on clopidogrel prior to the procedure.

Concluding this issue, compared with thromboelastography, there has been no study demonstrating the ability of rotational thromboelastometry to monitor the treatment response to antiplatelet drugs or to search for patients with HPR; however, several studies (although on limited samples) suggested that it can be used for procedural management of bleeding events in the settings of cardiac surgery.

2.6. Clinical Experiences with Viscoelastic Hemostatic Assays (VHA) for Platelet Function Testing and Gaps in Evidence

First, looking on the utility of VHA for PFT and monitoring of the response on antiplatelet drugs, the majority of evidence is for thromboelastography, for which assay-specific platelet mapping had been developed and is commercially available. As mentioned, the evidence for thromboelastometry is still limited to several low-sample studies reporting its usefulness for prediction of platelet-related bleeding and management of blood product transfusion in cardiac surgery. Second, looking more closely at the evidence for thromboelastography, one must conclude that the evidence is coming mostly from small sample non-randomized trials and clinical cases, and that there is no larger study confirming the results. This should always be taken into consideration when VHA is selected as a test for platelet function testing. Furthermore, although thromboelastography has been generally demonstrated as effective for prediction of antiplatelet drug response and for prediction of bleeding in patients on antiplatelet agents who need surgical (cardiac or non-cardiac) procedures, there are contradictions regarding these issues. Corliss et al. [84] reported poor correlation between the results of thromboelastography with a platelet mapping assay and Verify Now® analysis of platelet reactivity in patients who underwent cranial endovascular stenting procedures. In this retrospective single centre study, Verify Now® analysis accurately predicted thrombotic and hemorrhagic complications, while the maximal amplitude of thromboelastography ADP platelet mapping assay was not able to accurately predict these complications. In another study, Lam et al. [85] reported that thromboelastography with platelet mapping was, in their analysis of 141 patients with spontaneous intra-cerebral bleeding, unable to measure platelet inhibition (in those who were on antiplatelet agents) and was not a reliable method to guide platelet transfusion. Similar to this observation, Daley et al. [86] retrospectively analyzed a sample of 129 patients with acute trauma reported that there was no significant difference in thromboelastographic parameters of platelet function, including rate of arachidonic acid or ADP inhibition between patients on antiplatelet agents prior to injury and patients who did not take antiplatelet agents prior acute traumatic event. Therefore, thrombolastography alone should probably not be used to estimate the presence of antiplatelet drugs and, knowing the information for a patient taking an antiplatelet drug is still important. The question is what causes these contradictions. In fact, up to date, there is no satisfactory answer to this question. The most probable explanation is that the method has an apparent lack of specificity, as the initiation and propagation of coagulation process in VHA, including that with a platelet mapping assay, is unspecific and could be affected by various other confounding factors (such as platelet count, fibrinogen levels, liver dysfunction, tissue factor levels, etc.).

Second, there is an issue of correlation between TEG® Platelet Mapping™ Assay with other platelet function assays. In some respects, TEG platelet mapping could be inferior to VASP-P flow cytometry, considering the assay principles [43]. In fact, there is only one study directly evaluating the TEG Platelet Mapping Assay together with VASP-P flow cytometry in a sample of healthy volunteers who received clopidogrel therapy and three different proton pump inhibitors. In this study, Lee et al. [87] reported that both VASP-P and TEG platelet mapping showed the same general qualitative trend, but TEG® Platelet Mapping™ Assay detected a significant fluctuation of platelet aggregation in response to different proton pump inhibitors/clopidogrel interaction. As there is no other study comparing these two methods, this issue remains open for future resolution. Furthermore, when comparing TEG platelet mapping with Verify Now® and impedance aggregometry (Multiplate®), TEG
platelet mapping often comes third among these assays. This could be due to the fact that clinical experience with Verify Now® and Multiplate® is higher compared to TEG platelet mapping. However, when these three assays were compared with one another in 64 adult trauma patients (25 patients were taking antiplatelet drugs) in an observational study performed by Connelly et al. [88], there were no significant differences between assays and TEG® Platelet Mapping™ Assay, Verify Now® and Multiplate® correlated well and were able to identify aspirin-induced platelet dysfunction. On the other hand, in another study evaluating aspirin-induced platelet dysfunction by LTA, Verify Now®, Multiplate impedance aggregometry and TEG® Platelet Mapping™ Assay and clopidogrel-induced platelet dysfunction by the same methods and by VASP-P flow cytometry [89], the TEG® Platelet Mapping™ Assay was least suited to monitor antiplatelet agents-induced platelet dysfunction. Thus further studies are needed to raise final conclusions.

Third, all the platelet function tests based on platelet in vitro induction, including VHA with platelet mapping, measure platelet aggregation (as this is the key target of antiplatelet agents); they do not measure platelet adhesion. Therefore, it is necessary to use flow chamber techniques for the assessment of platelet adhesion [90]. Although the measurement of platelet adhesion is not generally needed in clinical practice, there are several clinical situations, in which impaired platelet adhesion is responsible for platelet dysfunction or platelet-related adverse events [91,92].

Fourth, it is not entirely clear what anticoagulation (citrated or hirudin or other) should be used for VHA platelet mapping. In a previous study the authors using blood samples from healthy volunteers compared LTA aggregation with different inducers (ADP, arachidonic acid, collagen, epinephrine and ristocetin) in samples collected to tubes with 3.2% trisodium citrate versus to tubes with recombinant hirudin (>15 µg/mL) [93]. The authors of this study reported that among all the agonists, hirudin-anticoagulated platelets had significantly weaker aggregation responses, possibly preferring citrated tubes for LTA platelet function testing. This should probably be applied also for VHA platelet mapping [48,80]; nevertheless, there is no study directly examining this issue in VHA platelet mapping, and therefore, there is no study for confirming this recommendation.

Concluding these issues, further research into the use of VHA in platelet function testing is still warranted.

3. Conclusions

Currently available data suggest possible clinical utility of thromboelastography with platelet mapping assay in the settings of predicting peri-operative bleeding in patients on antiplatelet agents who need surgical procedures and in the prediction of treatment response/antiplatelet therapy resistance on the most commonly used antiplatelet drugs. In addition, a limited number of studies suggested that thromboelastometry can be used for procedural management of platelet/antiplatelet therapy-related bleeding events in the settings of cardiac surgery. Nevertheless, due to limited data and the aforementioned unanswered issues, further research is still needed.

Author Contributions: M.S. and I.Š. designed the study, performed literature searches and drafted the manuscript; T.B. performed literature searches, analyzed the data and revised the manuscript; L.S. and B.K. analyzed the data; J.S., P.G., P.K. and M.M. revised and finalized the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by project APVV (Slovak Research and Development Agency) 16-0020, and by projects of the Research Agency of Slovak Ministry of Education, Science and Sports (VEGA) 1/0090/20 and 1/0549/19.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: All the data are available at Corresponding Author (matej.samos@gmail.com) upon reasonable request.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ACS          | acute coronary syndromes |
| ADP          | adenosinediphosphate |
| ADPRB        | ADP receptor blockers |
| ASA          | acetylsalicylic acid |
| CABG         | coronary artery bypass graft |
| CI           | confidence interval |
| GRAVITAS     | Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety |
| HPR          | high on-treatment platelet reactivity |
| HR           | hazard ratio |
| LTA          | light transmission aggregometry |
| MPR          | maximal platelet reactivity |
| PCI          | percutaneous coronary interventions |
| PFA          | Platelet Function Analyzer |
| PFT          | platelet function testing |
| POC          | point-of-care |
| PRI          | platelet reactivity index |
| PRP          | platelet rich plasma |
| PRU          | platelet response units |
| ROTEM®       | thromboelastometry |
| SCAD         | stable coronary artery disease |
| STEMI        | ST elevation myocardial infarction (MI) |
| TEG®         | thromboelastography |
| TRAP         | thrombin receptor activating peptide |
| VASP-P       | vasodilator-stimulated phosphoprotein (VASP) phosphorylation |
| VHA          | viscoelastic hemostatic assays |

References

1. Sibbing, D.; Byrne, R.A.; Kastrati, A. Role of platelet function testing in clinical practice: Current concepts and future perspectives. Curr. Drug Targets 2011, 12, 1836–1847. [CrossRef] [PubMed]
2. Aradi, D.; Sibbing, D.; Gross, L. Platelet Function Testing in Patients on Antiplatelet Medications. Semin. Thromb. Hemost. 2016, 42, 306–320. [CrossRef] [PubMed]
3. Janssen, P.W.A.; Berg, J.M.T. Platelet Function Testing and Tailored Antiplatelet Therapy. J. Cardiovasc. Transl. Res. 2013, 6, 316–328. [CrossRef] [PubMed]
4. Korpálová, B.; Samoš, M.; Bolek, T.; Škorňová, I.; Kovář, F.; Kubisz, P.; Staško, J.; Mokáň, M. Role of Thromboelastography and Rotational Thromboelastometry in the Management of Cardiovascular Diseases. Clin. Appl. Thromb. 2018, 24, 1199–1207. [CrossRef] [PubMed]
5. Larsen, J.B.; Hvas, A.M. Predictive Value of Whole Blood and Plasma Coagulation Tests for Intra- and Postoperative Bleeding Risk: A Systematic Review. Semin. Thromb. Hemost. 2017, 43, 772–805. [CrossRef] [PubMed]
6. Braunwald, E.; Angiolillo, D.; Bates, E.; Berger, P.B.; Bhatt, D.; Cannon, C.P.; Furman, M.I.; Gurbel, P.; Michelson, A.D.; Peterson, E.; et al. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin. Cardiol. 2008, 31, I17–I20. [CrossRef]
7. Bhatt, D.L.; Peacock, W.F.; Kottke-Marchant, K. Importance of platelets and platelet response in acute coronary syndromes. Cleve. Clin. J. Med. 2009, 76, S2–S7. [CrossRef]
8. Marcucci, R.; Gori, A.M.; Paniccia, R.; Giusti, B.; Valente, S.; Giglioli, C.; Buonamici, P.; Antoniucci, D.; Abbate, R.; Gensini, G.F. Car-diovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up. Circulation 2009, 119, 237–242. [CrossRef]
9. Marcucci, R.; Giusti, B.; Paniccia, R.; Gori, A.M.; Saracini, C.; Valente, S.; Giglioli, C.; Parodi, G.; Antoniucci, D.; Gensini, G.F.; et al. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets 2012, 23, 586–593. [CrossRef]
10. Siller-Matula, J.M.; Delle-Karth, G.; Christ, G.; Neunteufl, T.; Maurer, G.; Huber, K.; Tolios, A.; Drucker, C.; Jilma, B. Dual nonresponsiveness to antiplatelet treatment is a stronger predictor of cardiac adverse events than isolated non-responsiveness to clopidogrel or aspirin. *Int. J. Cardiol.* 2013, 167, 430–435. [CrossRef]

11. Droppa, M.; Tschernow, D.; Müller, K.A.L.; Tavlakí, E.; Karathanos, A.; Stimpfel, F.; Schaeffeler, E.; Schwab, M.; Tolios, A.; Siller-Matula, J.M.; et al. Evaluation of Clinical Risk Factors to Predict High On-Treatment Platelet Reactivity and Outcome in Patients with Stable Coronary Artery Disease (PREdict-STABLE). *PLoS ONE* 2015, 10, e0121620. [CrossRef] [PubMed]

12. Viviani Anselmi, C.; Briguiori, C.; Roncarati, R.; Papa, L.; Visconti, G.; Focaccio, A.; De Micco, F.; Latronico, M.V.; Pagnotta, P.; Conderolle, G. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical out-come following drug-eluting stent implantation in patients with stable coronary artery disease. *JACC Cardiovasc. Interv.* 2013, 6, 1166–1175. [CrossRef] [PubMed]

13. Siasos, G.; Oikonomou, E.; Zaromitiidou, M.; Kiousis, S.; Vavuranakis, M.; Maniatis, K.; Kokkou, E.; Papageorgiou, N.; Papaiannou, N.; Tourikis, P.; et al. High platelet reactivity is associated with vascular function in patients after percutaneous coronary intervention receiving clopidogrel. *Int. J. Cardiol.* 2014, 177, 192–196. [CrossRef] [PubMed]

14. Gianetti, J.; Parri, M.S.; Sbrana, S.; Paoli, F.; Maffei, S.; Faradossi, U.; Bertì, S.; Clerico, A.; Biagini, A. Platelet activation predicts re-current ischemic events after percutaneous coronary angioplasty: A 6 months prospective study. *Thromb. Res.* 2006, 118, 487–493. [CrossRef]

15. Wasilewski, J.; Desperak, P.; Hawranek, M.; Cislak, A.; Osadnik, T.; Pyka, Ł.; Gawlita, M.; Bujak, K.; Niedziela, J.; Krawczyk, M.; et al. Prognostic implications of mean platelet volume on short- and long-term outcomes among patients with non-ST-segment elevation myocardial infarction treated with percutaneous coronary intervention: A single-center large observational study. *Platelets* 2016, 27, 452–458. [CrossRef]

16. Bladowski, M.; Gawryś, J.; Gajecki, D.; Szahidewicz-Krupska, E.; Sawicz-Bladowska, A.; Doroszko, A. Role of the Platelets and Nitric Oxide Biotransformation in Ischemic Stroke: A Translative Review from Bench to Bedside. *Oxidative Med. Cell. Longev.* 2020, 2020, 1–18. [CrossRef]

17. Denorme, F.; De Meyer, S.F. The VWF-GPIb axis in ischaemic stroke: Lessons from animal models. *Thromb. Haemost.* 2016, 116, 597–604. [CrossRef]

18. VanRooy, M.J.; Pretorius, E. Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke. *Thromb. Res.* 2015, 135, 434–442. [CrossRef]

19. Rayt, H.S.; Merker, L.; Davies, R.S. Coagulation, Fibrinolysis, and Platelet Activation Following Open Surgical or Percutaneous Angioplasty Revascularization for Symptomatic Lower Limb Chronic Ischemia. *Vasc. Endovasc. Surg.* 2016, 50, 193–201. [CrossRef]

20. Maiocchi, S.; Alwis, I.; Wu, M.C.L.; Yuan, Y.; Jackson, S.P. Thrombo inflammatory Functions of Platelets in Ischemia–Reperfusion Injury and Its Dysregulation in Diabetes. *Semin. Thromb. Hemost.* 2018, 44, 102–113. [CrossRef]

21. Crafa, A.; Condorelli, R.A.; Mongioì, I.M.; Cannarella, R.; Barbagallo, F.; Aversa, A.; Izzo, G.; Perri, A.; Calogero, A.E.; La Vignera, S. Mean Platelet Volume as a Marker of Vasculogenic Erectile Dysfunction and Future Cardiovascular Risk. *J. Clin. Med.* 2020, 9, 2513. [CrossRef] [PubMed]

22. Rinaldi, M.J.; Gohs, F.X.; Kirtane, A.J.; Brodie, B.R.; Stuckey, T.D.; Redfors, B.; McAndrew, T.; Witzenbichler, B.; Weisz, G.; Neumann, F.-J.; et al. Impact of Point-of-Care Platelet Function Testing Among Patients with and Without Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention With Drug-Elluting Stents (from the ADAPT-DES Study). *Am. J. Cardiol.* 2019, 123, 549–557. [CrossRef] [PubMed]

23. De Rosa, R.; Palmerini, T.; De Servi, S.; Belmonte, M.; Crimi, G.; Cornara, S.; Calabrò, P.; Cattaneo, M.; Maffeo, D.; Tosò, A.; et al. High on-treatment platelet reactivity and outcome in elderly with non ST-segment elevation acute coronary syndrome–Insight from the GEPRESS study. *Int. J. Cardiol.* 2018, 259, 20–25. [CrossRef] [PubMed]

24. Price, M.J.; Berger, P.B.; Angiolillo, D.J.; Teirstein, P.S.; Tanguay, J.F.; Kandzari, D.E.; Cannon, C.P.; Topol, E.J. Evaluation of individu-alizedclopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. *Am. Heart J.* 2009, 157, 818–824. [CrossRef] [PubMed]

25. Li, X.; Wang, Z.; Wang, Q.; Xu, Q.; Lv, Q. Clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcome for acute coronary syndrome patients. *Basic Clin. Pharmacol. Toxicol.* 2019, 124, 84–93. [CrossRef] [PubMed]

26. Spectre, G.; Mosseri, M.; Abdelrahman, N.M.; Briskin, E.; Bulut, A.; Loncar, S.; Varon, D.; Alcalai, R. Clinical and prognostic im-plications of the initial response to aspirin in patients with acute coronary syndrome. *Am. J. Cardiol.* 2011, 108, 1112–1118. [CrossRef]

27. Beigel, R.; Hod, H.; Fefer, P.; Asher, E.; Novikov, I.; Shenkman, B.; Savion, N.; Varon, D.; Matezky, S. Relation of Aspirin Failure to Clinical Outcome and to Platelet Response to Aspirin in Patients with Acute Myocardial Infarction. *Am. J. Cardiol.* 2011, 107, 339–342. [CrossRef]

28. Aradi, D.; Gross, L.; Trenk, D.; Geisler, T.; Merkely, B.; Kiss, R.G.; Komócs, A.; Dézsi, C.A.; Ruzsa, Z.; Ungi, I.; et al. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: A pre-specified exploratory analysis from the TROPICAL-ACS trial. *Eur. Heart J.* 2019, 40, 1942–1951. [CrossRef]

29. Sato, T.; Namba, Y.; Kashihara, Y.; Tanaka, M.; Fuke, S.; Yamoto, A.; Saito, H. Clinical significance of platelet reactivity during prasugrel therapy in patients with acute myocardial infarction. *J. Cardiol.* 2017, 70, 35–40. [CrossRef]
30. Jariwala, P.; Bhatia, H.; Kumar, E.A.P. Sub-acute stent thrombosis secondary to ticagrelor resistance—Myth or reality!! Indian Hear. J. 2017, 69, 804–806. [CrossRef]

31. Mahla, E.; Tantry, U.S.; Schoeghuber, M.; Gurbel, P.A. Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. Anesthesiology 2020, 133, 1263–1276. [CrossRef] [PubMed]

32. Bolliger, D.; Lancel, M.D.; Siegemund, M. Point-of-Care Platelet Function Monitoring: Implications for Patients with Platelet Inhibitors in Cardiac Surgery. J. Cardiothorac. Vasc. Anesth. 2020, 21, 1053. [CrossRef]

33. Petrickevic, M.; Knezevic, J.; Biocina, B.; Mikus, M.; Konicos, L.; Rasic, M.; Milosevic, M.; Rotim, C.; Madzdar, T.; Rotim, A.; et al. Association among Clopidogrel Cessation, Platelet Function, and Bleeding in Coronary Bypass Surgery: An Observational Trial. Thorac. Cardiovasc. Surg. 2019. [CrossRef] [PubMed]

34. Björklund, E.; Hansson, E.C.; Romlin, B.S.; Jeppsson, A.; Malm, C.J. Postoperative platelet function is associated with severe bleeding in ticagrelor-treated patients. Interact. Cardiovasc. Thorac. Surg. 2018, 28, 709–715. [CrossRef] [PubMed]

35. Vlot, E.; Willemsen, L.M.; Van Dongen, E.P.; Janssen, P.W.; Hackeng, C.M.; Kloppenburg, G.T.; Kelder, J.C.; Berg, J.M.T.; Noordzij, P.G. Perioperative point of care platelet function testing and postoperative blood loss in high-risk cardiac surgery patients. Platelets 2018, 30, 982–988. [CrossRef]

36. Mahla, E.; Metzler, H.; Bornemann-Cimenti, H.; Prueller, F.; Raggam, R.; Pregartner, G.; Baumann, A.; Goerog, C.; Gurbel, P.A. Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery—The BIANCA Observational Study. Thromb. Haemost. 2018, 118, 864–872. [CrossRef]

37. Raggam, R.; Toller, W.; Mahla, E. Platelet function testing to time surgery in patients on dual antiplatelet therapy? Hämostaseologie 2014, 34, 40–45. [CrossRef]

38. James, T.W.; Thomson, B.J.; Naumann, D.N.; Stevenson, D.S. Platelet function testing in patients with post-operative tonsillotomy and adenoidectomy: measuring a possible early identifier of inherited platelet function disorders. J. Laryngol. Otol. 2020, 5, 1–5.

39. Dovlatova, N. Current status and future prospects for platelet function testing in the diagnosis of inherited bleeding disorders. Br. J. Haematol. 2015, 170, 150–161. [CrossRef]

40. Koltaï, K.; Kesmarky, G.; Fehér, G.; Tibold, A.; Toth, K. Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications. Int. J. Mol. Sci. 2017, 18, 1803. [CrossRef]

41. Dyzskiewicz-Korpanty, A.M.; Kim, A.; Burner, J.D.; Frenkel, E.P.; Sarode, R. Comparison of a rapid platelet function assay—Verify Now Aspirin—with whole blood impedance aggregometry for the detection of aspirin resistance. Thromb. Res. 2015, 120, 485–488. [CrossRef] [PubMed]

42. Cuisset, T.; Hamilos, M.; Sarma, J.; Sarno, G.; Wyffels, E.; Vanderheyden, M.; Barbato, E.; Bartunek, J.; De Bruyne, B.; Wijns, W. Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myocardial necrosis in patients undergoing elective coronary stenting for stable angina pectoris. Am. J. Cardiol. 2008, 101, 1700–1703. [CrossRef] [PubMed]

43. Fedor, M.; Samoš, M.; Simunová, R.; Fedorová, J.; Škorňová, I.; Duraj, L.; Staško, J.; Kovář, F.; Mokáň, M.; Kubíz, P. Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay. Clin. Appl. Thromb. Hemost. 2015, 21, 334–338. [CrossRef] [PubMed]

44. Lemesle, G.; Landel, J.B.; Bauters, A.; Delhaye, C.; Bonello, L.; Sudre, A.; Susen, S.; Bauters, C.; Lablanche, J.M. Poor agreement between light transmission aggregometry, Verify Now P2Y12 and vasodilator-stimulated phosphoprotein for clopidogrel low-response assessment: A potential explanation of negative results of recent randomized trials. Platelets 2014, 25, 499–505. [CrossRef] [PubMed]

45. Bolliger, D.; Seegerberger, M.D.; Tanaka, K.A. Principles and practice of thromboelastography in clinical coagulation manage-ment and transfusion practice. Transfu.s Med. Rev. 2012, 26, 1–13. [CrossRef]

46. Zaky, A. Thromboelastometry Versus Rotational Thromboelastometry in Cardiac Surgery. Semin. Cardiothorac. Vasc. Anesth. 2017, 21, 206–211. [CrossRef]

47. Whiting, D.; Dinardo, J.A. TEG and ROTEM: Technology and clinical applications. Am. J. Hematol. 2014, 89, 228–232. [CrossRef]

48. Tantry, U.S.; Bliden, K.P.; Gurbel, P.A. Overestimation of Platelet Aspirin Resistance Detection by Thrombelastograph Platelet Mapping and Validation by Conventional Aggregometry Using Arachidonic Acid Stimulation. J. Am. Coll. Cardiol. 2005, 46, 1705–1709. [CrossRef]

49. Alstrom, U.; Tydén, H.; Oldgren, J.; Siegbahn, A.; Stähle, E. The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. Thromb. Res. 2007, 120, 353–359. [CrossRef]

50. Bochslen, L.; Winberg, B.; Kjelgaard-Hansen, M.; Steinbrüchel, D.A.; Johansson, P.I. Evaluation of the TEG platelet mapping assay in blood donors. Thromb. J. 2007, 5, 3. [CrossRef]

51. Bochslen, L.; Nielsen, A.B.; Steinbrüchel, D.A.; Johansson, P.I. Higher Thrombelastograph platelet reactivity in cardiac surgery patients than in blood donors. Scand. Cardiovasc. J. 2007, 41, 321–324. [CrossRef] [PubMed]

52. Collwy, T.C.; Gray, D.J.; Sandhu, R.; Berridge, J.; Lyons, G. Assessment of platelet inhibition secondary to clopidogrel and aspi-rin therapy in preoperative acute surgical patients measured by Thrombelastography Platelet Mapping. Br. J. Anaesth. 2009, 102, 492–498. [CrossRef] [PubMed]

53. Preisman, S.; Kogan, A.; Itzkovsky, K.; Leikin, G.; Raanani, E. Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery. Eur. J. Cardiothorac. Surg. 2010, 37, 1367–1374. [CrossRef] [PubMed]
54. Weitzel, N.S.; Weitzel, L.B.; Epperson-Ford, A.; Tran, Z.V.; Seres, T. Platelet mapping as part of modified thromboelastography (TEG) in patients undergoing cardiac surgery and cardiopulmonary bypass. *Anesthesiology* 2012, 67, 1158–1165. [CrossRef] [PubMed]

55. Agarwal, S.; Johnson, R.I.; Kirmani, B.H. Pre- and Post-Bypass Platelet Function Testing with Multiple Electrode Aggregometry and TEG Platelet Mapping in Cardiac Surgery. *J. Cardiothorac. Vasc. Anesth.* 2015, 29, 1272–1276. [CrossRef]

56. Ellis, J.; Valencia, O.; Csern-Gilbert, A.; Phillips, S.; Meeran, H.; Sharma, V. Point-of-care platelet function testing to predict blood loss after coronary artery bypass grafting: A prospective observational pilot study. *Perfusion* 2016, 31, 676–682. [CrossRef] [PubMed]

57. Sivapalan, P.; Bäck, A.C.; Ostrowski, S.R.; Ravn, H.B.; Johansson, P.I. Transfusion requirements in elective cardiopulmonary by-pass surgery patients: Predictive value of Multiplate and Thromboelastography (TEG) Platelet Mapping Assay. *Scand. J. Clin. Lab Invest.* 2017, 77, 345–351. [CrossRef]

58. Barker, E.E.; Saini, A.; Gazit, A.Z.; Shea, S.M.; Baltagi, S.; Gage, B.F.; Spinella, P.C. TEG Platelet Mapping and Impedance Aggregometry to Predict Platelet Transfusion During Cardiopulmonary Bypass in Pediatric Patients. *Front Pediatr.* 2019, 7, 509. [CrossRef]

59. Tian, L.; Gao, X.; Yang, J.; Yao, Y.; Ji, H. Association of Adenosine Diphosphate–Induced Platelet Maximum Amplitude with Postoperative Bleeding and Blood Transfusions in Patients Undergoing Coronary Artery Bypass Grafting. *J. Cardiothorac. Vasc. Anesth.* 2021, 35, 421–428. [CrossRef]

60. Walsh, M.; Thomas, S.G.; Howard, J.C.; Evans, E.; Guyer, K.; Medvee, A.; Swearingen, A.; Navari, R.M.; Ploplis, V.; Castellino, F.J. Blood Component Therapy in Trauma Guided with the Utilization of the Perfusioneer and Thromboelastography. *J. Extra-corporeal Technol.* 2011, 43, 162–167.

61. Cattano, D.; Altamirano, A.V.; Kaynak, H.E.; Seitain, C.; Panicia, R.; Chen, Z.; Huang, H.; Prisco, D.; Hagberg, C.A.; Pivalizza, E.G. Perioperative assessment of platelet function by Thromboelastograph Platelet Mapping in cardiovascular patients undergoing non-cardiac surgery. *J. Thromb. Thrombol. 2013, 33, 23–30. [CrossRef] [PubMed]

62. Callender, R.; Altamirano, A.; Tezino, T.; Pivalizza, E.G.; Cattano, D. Is it possible? Predicting complications and morbidity in surgical patients on clopidogrel therapy with Platelet Mapping. *J. Orthop. Traumatol.* 2013, 15, 69–70. [CrossRef]

63. Kasivisvanathan, R.; Abbassi-Ghadi, N.; Kumar, S.; MacKenzie, H.; Thompson, K.; James, K.; Mallett, S.V. Risk of bleeding and adverse outcomes predicted by thromboelastography platelet mapping in patients taking clopidogrel within 7 days of non-cardiac surgery. *BJS 2014, 101, 1383–1390. [CrossRef] [PubMed]

64. Mamczak, C.N.; Maloney, M.; Fritz, B.; Boyer, B.; Thomas, S.; Evans, E.; Ploplis, V.A.; Castellino, F.J.; McCollester, J.; Walsh, M. Thromboelastography in Orthopaedic Trauma Acute Pelvic Fracture Resuscitation: A Descriptive Pilot Study. *J. Orthop. Trauma 2016, 30, 299–305. [CrossRef] [PubMed]

65. Liu, X.F.; Cao, J.; Fan, L.; Liu, L.; Li, J.; Hu, G.L.; Hu, Y.X.; Li, X.L. Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease. *J. Geriatr. Cardiol.* 2013, 10, 21–27. [PubMed]

66. Mir, A.; Frank, S.G.; Journeycake, J.; Wolovits, J.; Guleserian, K.; Heinstein, L.; Lemler, M.; Wolovits, J. Aspirin Resistance in Single-Ventricle Physiology: Aspirin Prophylaxis Is Not Adequate to Inhibit Platelets in the Immediate Postoperative Period. *Ann. Thorac. Surg.* 2015, 99, 2158–2164. [CrossRef] [PubMed]

67. Berganza, F.M.; Gonzalez de Alba, C.; Egbe, A.C.; Bartakian, S.; Brownlee, J. Prevalence of aspirin resistance by thromboelastography plus platelet mapping in children with CHD: A single-centre experience. *Cardiol. Young 2019, 29, 24–29. [CrossRef] [PubMed]

68. Morton, J.; Nelluri, S. Use of a thrombelastograph platelet mapping assay for diagnosis of clopidogrel resistance: A case report. J. Extra Corpor. Technol. 2009, 41, 32–36.

69. Jeong, Y.-H.; Bilden, K.P.; Antonino, M.J.; Tantry, U.; Gurbel, P.A. Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y12receptor inhibitors and high on-treatment platelet reactivity. *Platelets* 2012, 24, 166–169. [CrossRef]

70. Sun, B.; Li, J.; Dong, M.; Yang, L.; Wu, C.; Zhu, L.; Cong, Y. Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients. *Genet. Mol. Res.* 2015, 14, 1434–1442. [CrossRef]

71. Cheng, D.; Zhao, S.; Hao, Y. Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PIC patients. *Biosci. Rep.* 2020, 40, 20201346. [CrossRef] [PubMed]

72. Yang, Y.; Chen, W.; Pan, Y.; Yan, H.; Meng, X.; Liu, L.; Wang, Y.; Wang, Y. Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA. *Aging 2020, 12, 20085–20094. [CrossRef] [PubMed]

73. Qureshi, A.I.; Jahangir, M.U.; Qualls, K.; Akinici, Y.; Lobanova, I.; Liaqat, J.; Gao, X.; Akhtar, I.N.; Kraus, J.; Uzun, G.; et al. The Effect of Ticagrelor on Platelet Reactivity in Patients with Clopidogrel Resistance Undergoing Neuroendovascular Procedures. *J. Neuroimaging 2020, 30, 327–334. [CrossRef] [PubMed]

74. Ghamraoui, A.K.; Ricotta, J.J. Outcomes and strategy of tailored antiplatelet therapy with ticagrelor in patients undergoing transcatheter artery revascularization. *J. Vasc. Surg.* 2021, 73, 132–141. [CrossRef] [PubMed]

75. Zhang, J.H.; Tang, X.F.; Zhang, Y.; Wang, J.; Yao, Y.; Ma, Y.L.; Xu, B.; Gao, R.L.; Gao, Z.; Chen, J.; et al. Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. *Thromb. Res.* 2014, 134, 970–975. [CrossRef] [PubMed]
76. Samoš, M.; Staňciaková, L.; Duraj, L.; Kovár, F.; Fedor, M.; Šimonová, R.; Bolek, T.; Galajda, P.; Staško, J.; Kubisz, P.; et al. Monitoring the hemostasis with rotation thromboelastometry in patients with acute STEMI on dual antiplatelet therapy: First experiences. Medicine (Baltimore) 2017, 96, e6045. [CrossRef]

77. Scharbert, G.; Auer, A.; Kozek-Langenecker, S.A. Evaluation of the Platelet Mapping™ Assay on rotational thromboelastometry ROTEM®. Platelets 2009, 20, 125–130. [CrossRef]

78. Braun, D.; Knipper, A.; Orban, M.; Sibbing, D.; Petzold, T.; Braun, S.; Schulz, S.; Hausleiter, J.; Kastrati, A.; Mehilli, J.; et al. Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). Thromb. Res. 2016, 137, 72–78. [CrossRef]

79. Nissen, P.H.; Skipper, M.T.; Hvas, A.M. Whole blood platelet aggregation determined by the ROTEM platelet equipment; refer-ence intervals and stability. Platelets 2020, 31, 215–220. [CrossRef]

80. Kapoor, P.M.; Gorlinger, K.; Bhardwaj, V. Simulation in coagulation testing using rotational thromboelastometry: A fast emerging, reliable point of care technique. Ann. Card. Anaesth. 2016, 19, 516–520. [CrossRef]

81. Ogawa, S.; Szlam, F.; Chen, E.P.; Nishimura, T.; Kim, H.; Roback, J.D.; Levy, J.H.; Tanaka, K.A. A comparative evaluation of rota-tionthromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. Transfusion 2012, 52, 14–22. [CrossRef] [PubMed]

82. Tarzia, V.; Bortolussi, G.; Buratto, E.; Paolini, C.; Lin, C.D.; Rizzoli, G.; Bottio, T.; Gerosa, G. Single vs double antiplatelet therapy in acute coronary syndrome: Predictors of bleeding after coronary artery bypass grafting. World J. Cardiol. 2015, 7, 571–578. [CrossRef] [PubMed]

83. Azarfarin, R.; Noohi, F.; Kiavar, M.; Totonchi, Z.; Heidarpour, A.; Hendiani, A.; Koleini, Z.S.; Rahimi, S. Relationship between maximum clot firmness in ROTEM() and postoperative bleeding after coronary artery bypass graft surgery in patients using clopidogrel. Ann. Card. Anaesth. 2018, 21, 175–180. [PubMed]

84. Corliss, B.M.; Freedman, R.; Brennan, M.M.; Smith, J.; Nerva, J.D.; Harris, N.S.; Polifka, A.J.; Hoh, B.L.; Fox, W.C. Laboratory assessments of therapeutic platelet inhibition in endovascular neurosurgery: Complication prediction using the VerifyNow P2Y12 assay and thromboelastography with platelet mapping. J. Neurosurg. 2020, 1–9. [CrossRef] [PubMed]

85. Lam, H.; Katyal, N.; Parker, C.; Nattanamai, P.; Newey, C.R.; Kraus, C.K. Thromboelastography with Platelet Mapping Is Not an Effective Measure of Platelet Inhibition in Patients with Spontaneous Intracerebral Hemorrhage on Antiplatelet Therapy. Curesus 2018, 10, e2515.

86. Daley, M.J.; Trust, M.D.; Peterson, E.J.; Luftman, K.; Miller, A.H.; Ali, S.; Clark, A.; Aydelotte, J.D.; Coopwood, T.B.; Brown, C.V. Thromboelastography Does Not Detect Preinjury Antiplatelet Therapy in Acute Trauma Patients. Am. Surg. 2016, 82, 175–180. [CrossRef]

87. Lee, J.-K.; Wu, C.; Juang, J.-M.J.; Tsai, C.-T.; Hwang, J.-J.; Lin, J.-L.; Chiang, F.-T. Non-Carriers of Reduced-Function CYP2C19 Alleles Are Most Susceptible to Impairment of the Anti-Platelet Effect of Clopidogrel by Proton-Pump Inhibitors: A Pilot Study. Acta Cardiol. Sin. 2016, 32, 215–222.

88. Connelly, C.; Yonge, J.D.; McCully, S.P.; Hart, K.D.; Hilliard, T.C.; Lape, D.E.; Watson, J.J.; Rick, B.; Houser, B.; Deloughery, T.G.; et al. Assessment of three-point-of-care platelet function assays in adult trauma patients. J. Surg. Res. 2017, 212, 260–269. [CrossRef]

89. Karon, B.S.; Tolan, N.V.; Koch, C.D.; Wockenfus, A.M.; Miller, R.S.; Lingineni, R.K.; Pruthi, R.K.; Chen, D.; Jaffe, A.S. Precision and re-liability of 5 platelet function tests in healthy volunteers and donors on daily antiplatelet agent therapy. Clin. Chem. 2014, 60, 1524–1531. [CrossRef]

90. Schött, U.; Johansson, P.I., II. Brining flow into haemostasis diagnostics. Br. J. Anaesth. 2013, 111, 864–867. [CrossRef]

91. Israels, S.J.; Rand, M.L. What we have learned from inherited platelet disorders. Pediatr. Blood Cancer 2013, 60, S2–S7. [CrossRef] [PubMed]

92. Sonneveld, M.A.; de Maat, M.P.; Leebeek, F.W. Von Willebrand factor and ADAMTS13 in arterial thrombosis: A systematic review and meta-analysis. Blood Rev. 2018, 24, 168–178. [CrossRef] [PubMed]

93. Janse van Rensburg, W.J.; van der Merwe, P. Comparison of Commercially Available Blood Collection Tubes Containing Sodium Citrate and Hirudin in Platelet Aggregation Testing. Med. Sci. Monit. Basic Res. 2017, 23, 264–269. [CrossRef] [PubMed]